EP2284271A2 - Mutierte Luziferase - Google Patents

Mutierte Luziferase Download PDF

Info

Publication number
EP2284271A2
EP2284271A2 EP10178711A EP10178711A EP2284271A2 EP 2284271 A2 EP2284271 A2 EP 2284271A2 EP 10178711 A EP10178711 A EP 10178711A EP 10178711 A EP10178711 A EP 10178711A EP 2284271 A2 EP2284271 A2 EP 2284271A2
Authority
EP
European Patent Office
Prior art keywords
luciferase
amino acid
luciola
photinus pyralis
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10178711A
Other languages
English (en)
French (fr)
Other versions
EP2284271A3 (de
EP2284271B1 (de
Inventor
David James Squirrell
Tara Louise Willey
Melanie Jane Murphy
Peter John White
Rachel Louise Price
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promega Corp
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Priority claimed from EP00971589A external-priority patent/EP1224294B1/de
Publication of EP2284271A2 publication Critical patent/EP2284271A2/de
Publication of EP2284271A3 publication Critical patent/EP2284271A3/de
Application granted granted Critical
Publication of EP2284271B1 publication Critical patent/EP2284271B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)

Definitions

  • the present invention relates to a novel protein, in particular mutant luciferase enzymes which show distinctive properties as compared to corresponding wild type enzyme, to DNA encoding these proteins, to the use of these enzyme in assays and to test kits containing them.
  • Firefly luciferase catalyses the oxidation of luciferin in the presence of ATP, Mg 2+ and molecular oxygen with the resultant production of light. This reaction has a quantum yield of about 0.88.
  • the light emitting property has led to its use in a wide variety of luminometric assays where ATP levels are being measured. Examples of such assays include those which are based upon the described in EP-B-680515 and WO 96/02665 but many others are used routinely in laboratories.
  • Luciferase is obtainable directly from the bodies of insects, in particular beetles such as fireflies or glow-worms.
  • Particular species from which luciferases have been obtained include the Japanese GENJI or KEIKE fireflies, Luciola cruciata and Luciola lateralis, the East European firefly Luciola mingrelica, the North American firefly Photinus pyralis and the glow-worm Lampyris noctiluca.
  • the colour of the light emitted by these enzymes when used in assays in the laboratory are broadly similar. It would be helpful if the wavelength could be altered, either to be more easily read by the specific detector, or for use in systems where multiple reporters are required, for example to monitor different events within the same sample.
  • One way of distinguishing reporter molecules is to utilise luciferase molecules which emit light at distinct wavelengths. This may be achieved by using reporter molecules comprising luciferases derived from different species of beetle or glow-worm.
  • An alternative strategy however is to produce mutant luciferases using recombinant DNA technology, so as to produce a variation in the wavelength of the signal. Examples of such mutants are provided in WO 95/18853 .
  • the heat stability of wild and recombinant type luciferases is such that they lose activity quite rapidly when exposed to temperatures in excess of about 30°C, particularly over 35°C. This instability causes problems when the enzyme is used or stored at high ambient temperature, or if the assay is effected under high temperature reaction conditions, for example in order to increase reaction rate.
  • Mutant luciferases having increased thermostability are known from EP-A-524448 and WO/95/25798 .
  • the first of these describes a mutant luciferase having a mutation at position 217 in the Japanese firefly luciferase, in particular by replacing a threonine residue with an isoleucine residue.
  • mutant luciferases having over 60% similarity to luciferase from Photinus pyralis, Luciola mingrelica, Luciola cruciata or Luciola lateralis but in which the amino acid residue corresponding to residue 354 of Photinus pyralis or 356 of the Luciola species is mutated such that it is other than glutamate, and in particular is other than glutamate, aspartate, proline or glycine.
  • proteins which have luciferase activity and at least 60% similarity to wild-type luciferase such as those from Photinus pyralis, Luciola mingrelica, Luciola cruciata or Luciola lateralis enzyme, but which include mutations at various positions in the protein, including amongst others, (a) the amino acid residue corresponding to residue 214 in Photinus pyralis luciferase and to residue 216 of Luciola mingrelica, Luciola cruciata or Luciola lateralis luciferase; or
  • the applicants have found that by mutating (or introducing) an amino acid at a different position within the luciferase protein, large shifts in the wavelength of the emitted light may be achieved and/or the enzyme has improved thermostability. Furthermore, the proton flux of emitted light may be improved, making the enzyme better suited to in vivo assays where glow kinetics are precluded or in vitro assays where CoA or other 'glow kinetic inducing' compounds are not present.
  • the present invention provides a recombinant protein having luciferase activity and at least 60% similarity to a wild-type luciferase wherein in the sequence of the enzyme, the amino acid residue corresponding to residue 357 in Photinus pyralis luciferase is mutated as compared to the corresponding wild-type luciferase, such that the luciferase enzyme is able to emit light at a different wavelength as compared to the corresponding wild-type luciferase and/or has enhanced thermostability as compared to the corresponding wild-type luciferase.
  • Wild-type luciferase sequences which can form the basis of the recombinant forms of the invention include Photinus pyralis, Luciola mingrelica, Luciola cruciata or Luciola lateralis, Hotaria paroula, Pyrophorus plagiophthalamus Lampyris noctiluca, Pyrocoelia nayako, Photinus pennsylvanica or Phrixothrix (railroad-worms - see Biochem. 38 (1999) 8271-8279 ).
  • Bioluminescent enzymes from species that can use the substrate D-luciferin (4,5-dihydro-2-[6-hydroxy-2-benzothiazolyl]-4-thiazole carboxylic acid) to produce light emission may form the basis of the mutant enzymes of the invention.
  • Particular wild-type luciferase sequences which can form the basis of the recombinant forms of the invention include Photinus pyralis, Luciola mingrelica, Luciola cruciata or Luciola lateralis, Hotaria paroula, Pyrophorus plagiophthalmus Lampyris noctiluca, Pyrocoelia nayako and Photinus pennsylvanica.
  • the luciferases are enzymes obtainable from Photinus pyralis, Luciola mingrelica, Luciola cruciata or Luciola lateralis enzyme.
  • Luciola mingrelica, Luciola cruciata or Luciola lateralis enzymes the appropriate amino acid residue is at position 359 in the sequence.
  • amino acid residue corresponding to residue 357 in Photinus pyralis luciferase most wild-type sequences have an acid residue (aspartic acid or glutamic acid) at this position.
  • the exception to this is some forms of the luciferase of Photinus pennsylvanica in which the corresponding residue (355) is the non-polar residue, valine or some forms of Phrixothrix luciferase where the corresponding position is V354 in Pv GR or in Ph RE , where it is L354 leucine.
  • the amino acid used as a substitute amino acid at this position is other than aspartic acid, glutamic acid, valine or leucine.
  • an acidic amino acid residue is replaced with a non-acidic residue, including basic amino acids such as lysine or arginine, non-polar amino acids such as leucine, valine or isoleucine, uncharged polar amino acids such as tyrosine, asparagine, glutamine, phenylalanine, serine, tryptophan or threonine.
  • a non-acidic residue including basic amino acids such as lysine or arginine, non-polar amino acids such as leucine, valine or isoleucine, uncharged polar amino acids such as tyrosine, asparagine, glutamine, phenylalanine, serine, tryptophan or threonine.
  • it may be replaced with an uncharged polar amino acid such as tyrosine, asparagine, serine or threonine.
  • Particularly preferred amino acid residues for substitution at this position are tyrosine, phenylalanine or trypto
  • wild-type sequences include non-acidic amino acid residues at this position, they are suitably mutated into different non-acidic residues.
  • D357Y mutant Photinus pyralis luciferase emits light at a wavelength of some 612nm as compared to the wild-type enzyme which emits light at a wavelength of 562nm.
  • a wavelength shift of 50nm has considerable potential for use in assay applications as a shift of this magnitude can be readily defined spectrally.
  • Different coloured luciferases could be employed as reporter molecules in gene expression studies, enabling the simultaneous monitoring of more than one gene, for example as described in WO 95/18853 . Multiple analyte testing could also be performed with luciferase as labels.
  • red in colour is particularly useful in assay methodology.
  • a red mutant could be useful when analysing a solution for ATP which contained pigments or other compounds which may absorb shorter wavelengths of light.
  • a red coloured solution would not absorb red light.
  • red coloured solutions which are frequently the subject of such analysis include blood samples or a solution of eukaryotic cell culture medium which may contain a red coloured pH indicator.
  • a photomultiplier tube used in photocathode spectral analysis can be set to detect either one or both peaks generated in a single sample. In other words, it is possible to distinguish between photon flux from a red and green emitter in the same sample.
  • an assay for determining the presence in a sample of CoA comprises adding to a sample suspected of containing CoA, luciferase as described above together with other reagents which are required to bring about a luciferase/luciferin reaction, measuring the wavelength of light emitted from the sample and relating this to the presence or absence of CoA.
  • Such an assay may be useful in the detection of the state of growth or activity of cells, for example microorganisms or eukaryotic cells.
  • the concentration of C O A in E. coli cells is relatively high, and varies considerably with metabolic status.
  • the mutant enzymes of the invention can be used to monitor the metabolic status of an organism, particularly the in vivo concentration of the C O A, since the wavelength of the emission varies depending upon the C O A concentration.
  • Such assays may be particularly useful in situations where C O A is an important primary metabolite in the production of antibiotics (e.g. in streptomycetes).
  • Cellular CoA concentrations are also an important indicator of fatty acid biosynthesis and vary with the starvation status of the cell. A number of metabolic disorders such as carcinogenesis and diabetes, show abnormalities in the fatty acid metabolites and consequently unusual CoA levels.
  • Assays of the invention may be used in the diagnosis of such conditions.
  • the CoA levels from within a cell sample, such as a blood sample, from a patient may be determined by measuring the wavelength of light emitted from a luciferase of the invention, used in the assay. This result may be compared with that obtained from a sample of healthy cells to determine whether the wavelength has changed and thus that a modified CoA level is present. This may be indicative of a disease state in the patient.
  • Cells are suitably lysed prior to assay using a known lytic agent.
  • the bridging residues may be flexible enough to disengage when the enzyme is in solution to provide a larger pocket ( ⁇ 12 ⁇ deep and ⁇ 8 ⁇ wide) which allows CoA binding. This is consistent with the energy calculations.
  • the proteins may contain further mutations in the sequence provided the luciferase activity of the protein is not unduly compromised.
  • the mutations suitably enhance the properties of the enzyme or better suit it for the intended purpose in some way. This may mean that they result in enhanced thermostability and/or colour shift properties, and/or the K m for ATP of the enzymes. Examples of mutations which give rise to colour shifts are described in WO95/18853 . Mutations which affect K m values are described for example in WO 96/22376 and International Patent Application No. PCT/GB98/01026 .
  • mutant luciferases of the invention may include other specific mutations which enhance thermostability as compared to wild-type luciferase.
  • proteins of the invention are mutated wild-type luciferases where more than one amino acid, for example up to 100 amino acid residues, preferably no more than 40 amino acids, and more preferably up to 30 amino acids, are different to the amino acid at the corresponding position in the appropriate wild-type enzyme.
  • the protein of the invention comprises luciferase of Photinus pyralis, wherein, in addition to the mutation at the 357 position as described above, at least one of;
  • the protein of the invention comprises protein the luciferase sequence of Luciola mingrelica, Luciola cruciata or Luciola lateralis enzyme, and wherein, in addition to the mutation at position 359 as described above, at least one of
  • thermostability The particular substituted amino acids in any case which give rise to enhanced thermostability can be determined by routine methods as illustrated hereinafter. In each case, different substitutions may result in enhanced thermostability. Substitution may be effected by site-directed mutagenesis of DNA encoding native or suitable mutant proteins as would be understood by the skilled person. The invention in this case is associated with the identification of the positions which are associated with thermostability.
  • hydrophilic amino acid residues may, in some cases be preferably substituted with hydrophobic amino acid residues and vice versa.
  • acidic amino acid residues may be substituted with basic residues.
  • the protein may comprise a protein having luciferase activity and at least 60% similarity to luciferase from Photinus pyralis, Luciola mingrelica, Luciola cruciata or Luciola lateralis enzyme wherein in the sequence of the enzyme, at least one of;
  • the polar amino acid threonine is suitably replaced with a non polar amino acid such as alanine, glycine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan or cysteine.
  • a particularly preferred substitution for the threonine residue corresponding to residue 214 in Photinus pyralis is alanine.
  • a more preferred substitution is cysteine.
  • different polar residues such as asparagine at this position may also enhance the thermostability of the corresponding enzyme having threonine at this position.
  • luciferase enzymes include glycine (Luciola mingrelica, Hotaria paroula), asparagine ( Pyrophorus plagiophthalamus, GR, YG, YE and OR, Luciola cruciata, Luciola lateralis, Lampyris noctiluca, Pyrocelia nayako Photinus pennsylvanica LY, KW, J19 ) and serine ( Phrixothix ) . These may advantageously be substituted with non-polar or different non-polar side chains such as alanine and cysteine.
  • the nonpolar amino acid isoleucine is suitably replaced with a different non polar amino acid such as alanine, glycine, valine, lecine, proline, phenylalanine, methionine, tryptophan or cysteine.
  • alanine glycine
  • valine valine
  • lecine proline
  • phenylalanine methionine
  • tryptophan cysteine.
  • Other amino acids appearing at this position in wild type sequences include serine and asparagine.
  • these polar residues are substituted by non-polar residues such as those outlined above.
  • a particularly preferred substitution for the residue corresponding to residue 232 in Photinus pyralis luciferase and to residue 234 of Luciola mingrelica, Luciola cruciata or Luciola lateralis luciferase at group is alanine.
  • the non-polar amino acid phenylalanine is suitably replaced with a different non polar amino acid, such as alanine, leucine, glycine, valine, isoleucine, proline, methionine, tryptophan or cysteine.
  • a particularly preferred substitution for the phenylalanine residue corresponding to residue 214 in Photinus pyralis luciferase is leucine.
  • amino acid residue corresponding to amino acid 14 of the Photinus pyralis luciferase or to amino acid 16 in Luciola luciferase (13 in Phrixothrix luciferase) is also possible.
  • This amino acid residue (which is usually phenylalanine, but may also be leucine, serine, arginine or in some instances tyrosine) is suitably changed to a different amino acid, in particular to a different nonpolar amino acid such as alanine, valine, leucine, isoleucine, proline, methionine or tryptophan, preferably alanine.
  • Mutation at the amino acid residue corresponding to amino acid 35 of the Photinus pyralis luciferase or to amino acid residue 37 in Luciola mingrelica luciferase (38 in other Luciola spp.) may also be effective.
  • This amino acid varies amongst wild type enzymes, which may include leucine ( Photinus pyralis but also lysine, histidine, glycine, alanine, glutamine and aspartic acid at this position.
  • the amino residue at this position is substituted with a non-polar amino acid residue or a different non-polar amino acid such as alanine, valine, phenylalanine, isoleucine, proline, methionine or tryptophan.
  • a preferred amino acid at this position is alanine, where this is different to the wild-type enzyme.
  • Mutations at the amino acid corresponding to position 14 of the Photinus pyralis sequence and/or mutation at the amino acid residue corresponding to amino acid 35 of the Photinus pyralis luciferase are preferably not the only mutation in the enzyme. They are suitably accompanied by others of the mutations defined above, in particular those at positions corresponding to positions 214, 395 or 232 of Photinus pyralis luciferase.
  • Changes of the amino acid residue corresponding to residue 105 in Photinus pyralis luciferase and to residue 106 of Luciola mingrelica, Luciola cruciata or Luciola lateralis luciferase, (102 in Phrixothrix ) may also affect the thermostability of the protein.
  • the amino acid at this position is a non-polar amino acid alanine or glycine, or serine in Phrixothrix. These are suitably changed for different non-polar amino acids.
  • the non-polar amino acid alanine is suitably replaced with a different non polar amino acid, such as phenylalanine, leucine, glycine, valine, isoleucine, proline, methionine or tryptophan.
  • a particularly preferred substitution for the alanine residue corresponding to residue 105 in Photinus pyralis luciferase is valine.
  • Changes of the amino acid residue corresponding to residue 234 in Photinus pyralis luciferase and to residue 236 of Luciola mingrelica, Luciola cruciata or Luciola lateralis luciferase (231 in Phrixothrix ) may also affect the thermostability of the protein.
  • the amino acid at this position is aspartic acid or glycine and in some cases, glutamine or threonine. These are suitably changed for non-polar or different non-polar amino acids as appropriate.
  • the amino acid residue is aspartic acid is suitably replaced with a non polar amino acid, such as alanine, leucine, glycine, valine, isoleucine, proline, methionine or tryptophan.
  • a particularly preferred substitution for the phenylalanine residue corresponding to residue 234 in Photinus pyralis luciferase is glycine.
  • a non-polar amino acid residue such as glycine is present at this position (for example in Luciola luciferase)
  • this may be substituted with a different non-polar amino acid.
  • the amino acid at this position is an uncharged polar amino acid serine or threonine or glycine. These are suitably changed for different uncharged polar amino acids.
  • the serine may be replaced with asparagine, glutamine, threonine or tyrosine, and in particular threonine.
  • the amino acid residue at this position varies amongst the known luciferase proteins, being histidine in Photinus pyralis, Pyrocelia nayako, Lampyris noctiluca and some forms of Photinus pennsylanvanica luciferase, threonine in Luciola mingrelica, Hotaria paroula and Phrixothix (where it is amino acid 307) luciferase, valine in Luciola cruciata and Luciola lateralis, and asparagine in some Pyrophorus plagiophthalamus luciferase.
  • the amino acid at this position is hydrophilic amino acid which may be changed for a different amino acid residue which increases thermostability of the enzyme.
  • a particularly preferred substitution for the histidine residue corresponding to residue 310 in Photinus pyralis luciferase is arginine.
  • the protein also has the amino acid at position corresponding to amino acid 354 of the Photinus pyralis luciferase (356 in Luciola luciferase) changed from glutamate, in particular to an amino acid other than glycine, proline or aspartic acid.
  • the amino acid at this position is tryptophan, valine, leucine, isoleucine are asparagine, but most preferably is lysine or arginine.
  • This mutation is described in WO 95/25798 . It has been found that hydrophobic residues at this position enhance the wavelength shift of the enzyme, Furthermore, the presence of a large hydrophobic (V or I), polar (N) or positively charged (K or R) amino acid at position 354 enhances thermostability.
  • the protein also has the amino acid at the position corresponding to amino acid 217 in Luciola luciferase (215 in Photinus pyralis ) changed to a hydrophobic amino acid in particular to isoleucine, leucine or valine as described in EP-A-052448 .
  • Proteins of the invention include both wild-type and recombinant luciferase enzymes. They have at least 60% similarity to wild sequences such as those of Photinus pyralis, Luciole mangrelica, Luciola cruciata or Luciola lateralis enzyme in the sense that at least 60% of the amino acids present in the wild-type enzymes are present in the proteins of the invention. Such proteins can have a greater degree of similarity, in particular at least 70%, more preferably at least 80% and most preferably at least 90% to the wild-type enzymes listed above. Similar proteins are of this type include allelic variants, proteins from other insect species as well as recombinantly produced enzymes.
  • low stringency conditions can be defined as 3 x SCC at about ambient temperature to about 65°C, and high stringency conditions as 0.1 x SSC at about 65°C.
  • SSC is the name of a buffer of 0.15M NaCl, 0.015M trisodium citrate. 3 x SSC is three times as strong as SSC and so on.
  • the similarity of a particular sequence to the sequences of the invention may be assessed using the multiple alignment method described by Lipman and Pearson, ( Lipman, D.J, & Pearson, W.R. (1985) Rapid and Sensitive Protein Similarity Searches, Science, vol 227, pp1435-1441 ).
  • the sequences for which similarity is to be assessed should be used as the "test sequence” which means that the base sequence for the comparison, such as the sequence of Photinus pyralis or any of the other sequences as recorded in Ye et al., supra., should be entered first into the algorithm.
  • proteins of the invention are wild-type luciferase sequence with one or more of the mutations as outlined above.
  • the invention further provides nucleic acids which encode the luciferases as described above.
  • the nucleic acids are based upon wild-type sequences which are well known in the art. Suitable mutation to effect the desired mutation in the amino acid sequence would be readily apparent, based upon a knowledge of the genetic code.
  • the nucleic acid is a synthetic gene.
  • the synthetic gene is engineered to remove codons rarely found in highly expressed genes from common expression hosts such as E. coli and, at the same time, avoid the introduction of codons rarely found in genes coding for beetle luciferases. This approach ensures that the new gene has a codon utilisation that is optimal for both E. coli and insect expression systems.
  • the codons for the amino acids arg, leu, ile, gly and pro were changed to CGT or CGC (arg), CTG, CTT or CTC (leu), ATC or ATT (ile), GGT or GGC (gly), and CCG CCA or CCT (pro), thus eliminating rare codons.
  • the synthetic gene illustrated below (SEQ ID NO 1) and in Figure 14 this resulted in a total of 139 silent mutations creating 62 new non-rare codons (11% of the total).
  • the first 8 nucleotides shown in Figure 14 form part of the ribosome binding site and thus do not code.
  • the coding sequence begins with the methionine residue indicated by an up arrow. This coding sequence and closely similar sequences, for example sequences which have at least 90% similarity or preferably at least 95% similarity form a preferred aspect of the invention.
  • Another useful feature which may be employed when producing a synthetic assembly is the incorporation of new unique restriction sites. These sites make mutagenesis, in particular combinatorial cassette mutagenesis, of the gene simpler and more efficient. In particular, it may be desirable to create unique restriction sites within the cDNA coding for subdomain B in the enzyme. Additionally creation of a unique restriction site at the extreme 3' end of the gene to allow simple fusions and/or removal of the peroxisome targeting sequence may be advantageous.
  • thermostabilising amino acid changes T214C, E354K and D357F were engineered to introduce the thermostabilising amino acid changes T214C, E354K and D357F into the polypeptide.
  • the nucleic acids of the invention are suitably incorporated into an expression vector such as a plasmid under the control of control elements such as promoters, enhancers, terminators etc.
  • a host cell for example a prokaryotic or eukaryotic cell such as a plant or animal cell, but in particular a prokaryotic cell such as E. coli so that the cell expresses the desired luciferase enzyme.
  • Culture of the thus transformed cells using conditions which are well known in the art will result in the production of the luciferase enzyme which can then be separated from the culture medium.
  • the cells are plant or animal cells, plants or animals may be propagated from said cells.
  • the protein may then be extracted from the plants, or in the case of transgenic animals, the proteins may be recovered from milk.
  • Vectors, transformed cells, transgenic plants and animals and methods of producing enzyme by culturing these cells all form further aspects of the invention.
  • the Photinus pyralis D357Y mutant luciferase was created by random mutagenesis as described hereinafter. It was found that the D357Y single point mutation produces a large colour shift in the wavelength of light emitted and also has greater thermostability than wild type luciferase. Further investigations have revealed that a range of substitutions at this position give rise to good thermostability and/or to large colour shifts.
  • mutant enzymes of Photinus pyralis which fall within the scope of the invention include the following:
  • the mutations for the creation of the above mutants were introduced to the luciferase gene on plasmid pET23 by site-directed mutagenesis, (PCR) or combinatorial cassette mutagenesis.
  • PCR site-directed mutagenesis
  • the oligonucleotides added to the PCR reaction in order to effect the relevant mutations are given below.
  • Luciferase proteins of the invention will advantageously be employed in any bioluminescent assay which utilises the luciferase/luciferin reaction as a signalling means. There are many such assays known in the literature. The proteins may therefore be included in kits prepared with a view to performing such assays, optionally with luciferin and any other reagents required to perform the particular assay.
  • Two libraries of firefly ( Photinus pyralis ) luciferase created used error-prone PCR [ M. Fromant et al., Anal. Biochem. (1995) 224, 347-353 ], were prepared.
  • One library comprised of error-prone PCR products of the full length luc gene, cloned into the T7 expression system pET23a, (Novagen Inc., Madison, WI, U.S.A.).
  • a second library consisted of the error-prone PCR products of a short section of the luc gene, covering amino acids 199-352, cloned in the vector pBSK(+), (Stratagene, La Jolla, CA, U.S.A.).
  • the pET23a library was expressed in E. coli strain BL21(DE3), ( E. coli B F dcm ompT hsdS (r B - m B - ) gal ⁇ (DE3)).
  • the pBSK(+) library was expressed in HB101 E. coli cells, ( supE44 araI4 galK2 lacY1 ⁇ ( gpt-proA ) 62 rpsL20 ( Str r ) xyl-5 mtl-1 recA13 ⁇ ( mrcC-mrr ) HsdS - ( r - m - ) .
  • pET23a and pBSK(+) both carry the gene for ⁇ -lactamase and confer ampicillin resistance to E. coli cells harbouring the plasmid.
  • An E. coli strain was transformed with the prepared library by electroporation, using a BIORAD E. coli Pulser, and grown overnight at 37°C on LB agar, containing ampicillin at a concentration of 50 ⁇ g/ml.
  • the cells were transferred to nylon membranes, (Osmonics, Minnetonka, Minnesota, U.S.A.), and sprayed with luciferin solution (500 ⁇ M D-luciferin, potassium salt, in 100mM sodium citrate buffer, pH 5.0).
  • the colonies were viewed using an AlphaImager TM 1200 Documentation and Analysis System (Flowgen, Lichfield, Staffordshire, UK). This integrated the bioluminescence emitted over a specified period of time to produce an image of the light emitted by the colonies. The brightness of luminescence was taken as an indication of the thermostability of luciferase.
  • thermostability Colonies were selected on the basis of brightness of light emitted and were isolated for further characterisation. In some screens, the E. coli colonies were incubated at 42°C for 2 hours prior to screening so that the thermostable mutants could be selected. Colonies isolated from the primary screen were patched onto nylon membranes and also grown overnight in LB medium containing ampicillin. The patches were sprayed with luciferin solution and viewed in the AlphaImager TM . This secondary screen helped to positively identify clones for in vitro analysis of luciferase activity. E. coli clones expressing possible thermostable enzymes were assayed in vitro for luciferase activity and thermostability.
  • the luciferase reaction was initiated by the addition of 10 ⁇ l crude cell extract to 100 ⁇ l Promega Luciferase Assay Cocktail (1 in 2 dilution). The resultant bioluminescence was measured using a Biotrace M3 luminometer.
  • Crude cell extracts were prepared as described in the Promega technical bulletin no. 101. Aliquots of E. coli overnight cultures were lysed in cell culture lysis reagent, (25mM Tris-phosphate pH7.8, 2mM dithiothreitol (DTT), 2mM 1,2-diaminocyclohexame-N,N,N',N'-tetraacetic acid, 10% glycerol, 1% Triton X-100, 1.25 mg/ml hen lysozyme) for 10 minutes at room temperature. Crude lysate were then stored on ice prior to assay.
  • DTT dithiothreitol
  • Triton X-100 1.25 mg/ml hen lysozyme
  • T 1/2 is the time taken for the enzyme to lose 50% of its original activity after incubation at a given temperature. T 1/2 values, (time for activity to reduce to 50% of original activity), were determined in crude extracts at 37°C from log graphs of % remaining activity versus time (not shown).
  • Plasmid DNA was prepared using the QIAGEN QIAprep Spin Miniprep Kit, (QIAGEN Ltd, Crawley, W.shire, UK), following the protocol for using a microcentrifuge (QIAprep Miniprep Handbook 04/98).
  • D357Y is a particularly thermostable mutant, being the most thermostable luciferase, with a single amino acid change.
  • site-directed mutagenesis was performed using the Stratagene QuikChange TM Site-Directed Mutagenesis Kit, (Stratagene, La Jolla, CA, U.S.A.).
  • the plasmid pPW601a J54, (PJW, MoD Report, 3/96) was used in all site-directed mutagenesis. All products of the mutagenesis reactions were transformed into E.
  • Oligonucleotide primers were synthesized by Sigma-Genosys Ltd., Cambridge, UK and were designed using an intelligent doping system [ A.R Arkin et al., Bio-technology, (1992)10, 297-300 , W,. Huang et al., Anal. Biochem. 218, 454-457 ] were used to design degenerate oligonucleotide primers to produce groups of possible mutations rather than using individual primers for each amino acid substitution
  • N is the number of colonies to be screened
  • n is the number of possible codons at the target position
  • the mutants obtained from site-directed mutagenesis were assayed for luciferase activity and characterised in time-dependent thermoinactivation studies.
  • Mutants identified as desirable in this way were grown in 400ml LB medium, containing ampicillin, to A 260 ⁇ 0.5. Luciferase expression was then induced by addition of isopropyl ⁇ -thiogalactoside (IPTG) to a final concentration of 1mM. The cells were then incubated at 30°C, with shaking, for 3 hours prior to harvesting by centrifugation. The resultant cell pellet was resuspended in 10ml B-PER TM Protein Extraction Reagent, (Pierce Chemical Company, Rochford, U.S.A.), 1mM DTT to produce a crude extract, following the B-PER TM protocol for Maxi-Scale Bacterial Protein Extraction.
  • the supernatant of the crude extract was subjected to fractionation with ammonium sulphate.
  • the fraction that precipitated between 30% and 55% saturation contained luciferase activity.
  • This material was resuspended in 0.5ml Tris HCl pH8.0, 1mM DTT and used for thermoinactivation and spectral studies.
  • thermoinactivation buffer 50mM potassium phosphate buffer pH7.8 containing 10% saturated ammonium sulphate, 1mM dithiothreitol and 0.2% BSA.
  • the in vivo luminescence of the mutants was assessed by eye in a dark room.
  • the D357 mutants displayed a variety of colours in their luminescence spectra.
  • D357Y, F and I showed significant shifts to longer wavelengths of emitted light.
  • Recombinant wild type (r-wt) enzyme was used for comparison of ⁇ max of in vivo light emission of some of the 357 mutants.
  • D357Y, F and I display considerable shifts in their wavelength maxima.
  • D357Y was partially purified by ammonium sulphate precipitation, as described in the Example 1. This partially purified D357Y enzyme (5 ⁇ l) was mixed with 150 ⁇ l Promega Luciferase Assay Reagent. Another aliquot was mixed with an equivalent assay buffer in which CoA is absent, (25mM Tris Tricine pH7.8, 5.0mM MgSO 4 0.1mM EDTA, 2mM DTT, 470 ⁇ M D-luciferin, 530 ⁇ M ATP). The emission spectra of the two reactions were measured and are shown in Figures 9 and 10 .
  • the spectra display a marked difference in bioluminescent emission in the absence and presence of CoA, with dramatic shift in ⁇ max .
  • the effect of CoA on the kinetics of the luciferase reaction can also be seen by in the difference in RLU scales. (RLU - Relative Light Units).
  • the double mutant displayed a marked increase in thermostability in comparison to the single mutants E3541 and D357Y individually, (see Figure 3 ).
  • Thermoinactivation studies of partially purified double mutant confirmed the increased thermostability of the mutant, giving a t 1/2 value of '7.7 min when inactivated at 45°C.
  • the double mutant displays a much deeper red colour of luminescence than the individual mutants of E3541 and D357Y, displaying additivity of colour of luminescence.
  • Emission spectra measured in vivo give a ⁇ max of 611nm. However, the spectrum has a greater contribution of luminescence from the red region of wavelengths, leading to its deeper red appearance when visualised by eye.
  • Emission spectra in crude extracts displayed a definite change in spectral shape and a wavelength shift of 44nm, relative to rWT, (see Figure 4 ) .
  • the in vivo emission spectrum of the double mutant shows both a sharpening of the bandwidth for the peak wavelength of emitted light (613nm) and a decrease in the contribution from wavelengths of light in the region 540-560nm.
  • the in vivo bioluminescence of E. coli cells expressing the mutant D357K was observed to be vary bright relative to the other mutants at this position.
  • the flash kinetics of this enzyme was analysed using a luminometer, which could measure the rate of photon emission over time. Aliquots of E. coli cell free extracts containing recombinant wild type enzyme or the mutant D357 were added to a luciferase assay cocktail, which did not contain any reagents that would promote glow kinetics e.g. coenzymeA.
  • the rate of decay of photon emission was measured over time (15s) for both enzymes was observed to be significantly slower for the mutant D357K ( Figure 4 ) .
  • the mutant enzyme has reaction kinetics, which are inhibited to a lesser degree, over at least the first 15 seconds of the reaction, than the recombinant wild type enzyme.
  • Two new unique restriction sites were introduced into the luc gene, in the plasmid pPW601a/J54, using two pairs of synthetic oligonucleotides (see below).
  • a total of six silent mutations introduced a SpeI and a KpnI restriction site, 63 base pairs apart, within the gene. Plasmid containing these new sites was called pPW601aJ54SpeI/KpnI.
  • the presence and proximity of these restriction sites makes it possible to use combinatorial cassette mutagenesis to explore the effects of random substitutions at amino acid positions 354 and 357 in the primary sequence of firefly luciferase.
  • a pair of synthetic oligonucleotides was synthesised which when annealed created a double stranded cassette which could be ligated directly into Plasmid pPW601aJ54SpeI/KpnI digested at the new restriction sites.
  • the cassette was designed to introduce all possible combinations of the 20 naturally occurring amino acids at positions 354 and 357 in the primary sequence.
  • each of the loop library oligonucleotides was mixed in a buffer containing 50mM Tris-HCl pH 7.4, 25mM NaCl, and heated to 100°C for 3min. This solution was then cooled slowly in a heating block to ⁇ 50°C to anneal the complimentary sequences. The annealed oligonucleotides were then ligated into plasmid pPW601aJ54SpeI/KpnI, which had been digested with SpeI and KpnI. Aliquots of the ligation reaction were then used to transform E. coli Hub101 cells using electroporation.
  • Plasmid DATA was prepared from the 25 clones selected by in vivo screening and sequenced using gene specific sequencing primers. Mutations resulting in amino acid changes at positions 354 and 357 in the primary sequence were identified. One mutant, also contained an additional mutation resulting in an amino acid substitution at position I351 (Table 5).
  • mutant luciferases were selected from the in vivo assays for thermostability. The majority of these luciferases also show large changes in the in vivo spectrum of emitted light with many showing greater contributions from longer wavelengths of light (>580nm). A number of spectra also showed a significant narrowing of bandwidth around a single peak of 610-614nm.
  • E354 and D357 with a hydrophobic and an aromatic amino acid respectively e.g. E354V, D357Y results in the largest change in the in vivo spectrum which shows a single peak, of narrow bandwidth, around 612nm.
  • Cell free extracts of the selected clones were prepared by lysis and the thermostability of the luciferase from each extract was determined in a thermal inactivation experiment. 50 ⁇ l of each extract was placed in an eppendorf tube and incubated in a waterbath heated to 45°C for 4, 9 and 16 minutes. At the appropriate timepoint the aliquot was removed and the remaining luciferase activity measured. Table 6 shows the percent remaining activity versus time for all mutant enzymes as well as recombinant wild type. Table 6 Enzyme No.
  • thermostable luciferases were those with an aromatic amino acid at position 357 (Y, F. our W) and a large hydrophobic (V or I), polar (N) or positively charged (K or R) amino acid at position 354.
  • a 50ml culture of cells was grown to mid log phase on LB medium and then harvested by centrifugation.
  • the cell pellet was resuspended in 1ml of sterile distilled water and a 100ul aliquot of this suspension was then used to inoculate 5ml of fresh LB, M9 minimal medium + 2mM sodium acetate or M9 minimal medium + 2mM glucose in a 25ml Sterilin tube.
  • the cultures were allowed to continue growing, at 37°C with shaking, and after 90 minutes (D357Y) or 120 minutes (enzyme 7) a 200 ⁇ l aliquot of cells was removed centrifuged and resuspended in 150ul of 100mM sodium citrate buffer pH 5.0 containing 0.5mM D-luciferin.
  • Recombinant wild type Photinus pyralis enzyme and the mutant luciferases D357Y and E354I + D357Y were purified to homogeneity in order to analyse the effect of the cofactor coenzyme A on the spectrum of the bioluminescent reaction. All three luciferases were purified as fusions to a 143 amino acid carbohydrate binding module (CBM) from the anaerobic fungus Piromyces equii. This CBM has been shown to bind selectively to acid swollen cellulose and the soluble carbohydrates galactomannan and glucomannan, forming the basis for a simple single step affinity purification scheme.
  • CBM carbohydrate binding module
  • Luciferases fused to the CBM can be bound to cellulose in crude cell free extracts, washed, and then eluted selectively using soluble polysaccharides. Fusion proteins purified this way were used in assays to measure the wavelengths of emitted light in reactions containing different amounts of coenzyme A.
  • Enzyme (5 ⁇ l) was added to 100 ⁇ l of assay reagent, 25mM Tris-Tricine pH 7.8, 5.0mM MgSO4, 0.1mM EDTA, 530 ⁇ M ATP and 470 ⁇ M D-luciferin, containing different amounts of coenzyme A.
  • Figures 9-11 show the effect of increasing concentrations of coenzyme A on the spectrum of light emitted by the purified luciferases D357 and E354I + D357Y.
  • a synthetic luc gene was designed and assembled from oligonucleotide pairs using the synthesis strategy outlined above.
  • the gene sequence was engineered to create a luciferase with the amino acids 214C, 354K and 357F.
  • oligonucleotides Twenty-nine pairs of overlapping synthetic oligonucleotides were synthesised by Sigma-Genosys Ltd, purified by PAGE and ligated in three assemblies of approximately 550bp (IDRIS 1,2 & 3, Figure 13 ). Each assembly was then ligated separately into the vector pBSK(+) and the resulting constructs were used to transform E. coli XL1-Blue cells. Plasmid DNA was prepared from clones containing the assembled inserts and sequenced to confirm the fidelity of the ORFs. The presence of n-1 oligonucleotides (by-products of the oligosynthesis) in the assemblies complicated the build process.
  • DNA sequencing identified a single correct assembly of IDRIS 2 and the PCR was used to correct one assembly of IDRIS 3 which contained a single base pair deletion at the 5' end of the construct. Assembly of the complete ORF was achieved by ligating a mixture of plasmids containing IDRIS 1 with IDRIS 2 and 3.
  • the ligated DNA was then used to transform E. coli XL1-Blue cells and clones expressing active enzyme were selected using an in vivo assay. Several clones were selected and sequenced to confirm the presence and fidelity of the synthetic luc gene having the sequence shown in Figure 14 .
  • the complete ORF was called IDRIS (FA).
  • the synthetic gene was assembled into the vector pBSK(+) between the BamH I and Sal I sites in the polylinker. In this position the gene is not in frame with the alpha peptide and is a significant distance from the lac promoter. However, enough luciferase is produced to enable preliminary characterisation of the enzyme. Crude cell free extracts of E. coli XLl-Blue cells expressing IDRIS (FA) were prepared, from overnight cultures, using the Promega lysis method.
  • thermostability of the enzyme in the extract was then tested at 50°C over 20 minutes and compared with the thermostable mutant E354I+D357Y.
  • the new codon optimised triple mutant was significantly more thermostable than the mutant E354I+D357Y ( Figure 15 ).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
EP10178711.7A 1999-10-26 2000-10-26 Mutierte Luziferase Expired - Lifetime EP2284271B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9925161.3A GB9925161D0 (en) 1999-10-26 1999-10-26 Novel enzyme
EP00971589A EP1224294B1 (de) 1999-10-26 2000-10-26 Mutantenluciferase
EP07017621.9A EP1935980B1 (de) 1999-10-26 2000-10-26 Luziferasemutante

Related Parent Applications (4)

Application Number Title Priority Date Filing Date
EP07017621.9A Division EP1935980B1 (de) 1999-10-26 2000-10-26 Luziferasemutante
EP00971589.7 Division 2000-10-26
EP00971589A Division EP1224294B1 (de) 1999-10-26 2000-10-26 Mutantenluciferase
EP07017621.9 Division 2007-09-08

Publications (3)

Publication Number Publication Date
EP2284271A2 true EP2284271A2 (de) 2011-02-16
EP2284271A3 EP2284271A3 (de) 2012-03-07
EP2284271B1 EP2284271B1 (de) 2013-09-11

Family

ID=10863292

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10178711.7A Expired - Lifetime EP2284271B1 (de) 1999-10-26 2000-10-26 Mutierte Luziferase
EP07017621.9A Expired - Lifetime EP1935980B1 (de) 1999-10-26 2000-10-26 Luziferasemutante

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP07017621.9A Expired - Lifetime EP1935980B1 (de) 1999-10-26 2000-10-26 Luziferasemutante

Country Status (5)

Country Link
US (2) US8669087B1 (de)
EP (2) EP2284271B1 (de)
JP (1) JP2011083289A (de)
GB (2) GB9925161D0 (de)
ZA (1) ZA200203170B (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102191213A (zh) * 2011-04-14 2011-09-21 中国科学院武汉病毒研究所 一种萤火虫荧光素酶的编码基因及制备方法和应用
US8809529B2 (en) 2010-11-02 2014-08-19 Promega Corporation Imidazo[1,2-α]pyrazine derivatives
US9487520B2 (en) 2010-11-02 2016-11-08 Promega Corporation Coelenterazine derivatives and methods of using same
US9790537B2 (en) 2014-01-29 2017-10-17 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements
US9927430B2 (en) 2014-01-29 2018-03-27 Promega Corporation Pro-substrates for live cell applications

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
JP6412718B2 (ja) * 2014-05-27 2018-10-24 オリンパス株式会社 プロモーターアッセイ
US9732373B2 (en) 2014-09-11 2017-08-15 Promega Corporation Luciferase sequences utilizing infrared-emitting substrates to produce enhanced luminescence
JP6493316B2 (ja) 2016-06-21 2019-04-03 東亜ディーケーケー株式会社 変異型甲虫ルシフェラーゼ、遺伝子、組換えベクター、形質転換体、及び変異型甲虫ルシフェラーゼの製造方法
WO2019081620A1 (en) * 2017-10-25 2019-05-02 Roche Diagnostics Gmbh IMPROVED MODIFIED / MUTANT BACTERIAL LUCIFERASES

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052448A1 (de) 1980-11-12 1982-05-26 Mita Industrial Co. Ltd. Photoempfindliche Trommel für ein elektrostatisches Kopiergerät
EP0524448A1 (de) 1991-06-27 1993-01-27 Kikkoman Corporation Thermostabile Luciferase des Leuchtkäfers, Gen der thermostabilen Luciferase des Leuchtkäfers, rekombinante DNS, und Verfahren zur Herstellung der thermostabilen Luciferase des Leuchtkäfers
WO1995018853A1 (en) 1994-01-03 1995-07-13 Promega Corporation Mutant luciferases
WO1995025798A1 (en) 1994-03-23 1995-09-28 The Secretary Of State Of Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Luciferases
WO1996002665A1 (en) 1994-07-13 1996-02-01 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Microbiological test method and reagents
WO1996022376A1 (en) 1995-01-20 1996-07-25 The Secretary Of State For Defence Mutant luciferases
EP0680515B1 (de) 1993-01-21 1998-08-26 The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Mikrobiologisches testverfahren und reagenzien

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
JPH088864B2 (ja) 1988-04-12 1996-01-31 キッコーマン株式会社 ルシフェラーゼ
US5049358A (en) 1988-09-30 1991-09-17 Miles Inc. Composition and test device for assaying for proteins
US5196524A (en) 1989-01-06 1993-03-23 Eli Lilly And Company Fusion reporter gene for bacterial luciferase
US5219737A (en) 1990-03-27 1993-06-15 Kikkoman Corporation Mutant luciferase of a firefly, mutant luciferase genes, recombinant dnas containing the genes and a method of producing mutant luciferase
US5480789A (en) 1991-04-01 1996-01-02 Florigene Europe B.V. Genetically transformed rose plants and methods for their production
JP3048466B2 (ja) 1991-06-27 2000-06-05 キッコーマン株式会社 耐熱性ホタルルシフェラーゼ、耐熱性ホタルルシフェラーゼ遺伝子、新規な組み換え体ｄｎａ、及び耐熱性ホタルルシフェラーゼの製造法
US6387675B1 (en) 1994-01-03 2002-05-14 Promega Corporation Mutant luciferases
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB2301592B (en) 1994-03-23 1998-06-17 Secr Defence Luciferases
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5716851A (en) 1996-01-16 1998-02-10 Bayer Corporation Glass/cellulose as protein reagent
JPH09294600A (ja) 1996-04-26 1997-11-18 Kikkoman Corp 複数のプロモーター活性の測定法
JP2001504325A (ja) 1996-09-27 2001-04-03 マキシジェン，インコーポレイテッド 回帰的配列シャフリングおよび選択による遺伝子治療の最適化のための方法
GB9707486D0 (en) 1997-04-11 1997-05-28 Secr Defence Enzyme assays
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
CA2301828A1 (en) * 1997-09-19 1999-03-25 Promega Corporation Thermostable luciferases and methods of production
GB9823468D0 (en) 1998-10-28 1998-12-23 Secr Defence Novel enzyme
NZ518413A (en) * 1999-10-26 2004-11-26 Secr Defence Novel enzyme
US7083911B2 (en) 2001-02-16 2006-08-01 Promega Corporation Method for detection of ATP
US7183092B2 (en) * 2003-10-03 2007-02-27 Board Of Control Of Michigan Technological University Modified luciferase
JP5244942B2 (ja) 2011-04-25 2013-07-24 株式会社グレイプ 筋交い取付構造

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052448A1 (de) 1980-11-12 1982-05-26 Mita Industrial Co. Ltd. Photoempfindliche Trommel für ein elektrostatisches Kopiergerät
EP0524448A1 (de) 1991-06-27 1993-01-27 Kikkoman Corporation Thermostabile Luciferase des Leuchtkäfers, Gen der thermostabilen Luciferase des Leuchtkäfers, rekombinante DNS, und Verfahren zur Herstellung der thermostabilen Luciferase des Leuchtkäfers
EP0680515B1 (de) 1993-01-21 1998-08-26 The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Mikrobiologisches testverfahren und reagenzien
WO1995018853A1 (en) 1994-01-03 1995-07-13 Promega Corporation Mutant luciferases
WO1995025798A1 (en) 1994-03-23 1995-09-28 The Secretary Of State Of Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Luciferases
WO1996002665A1 (en) 1994-07-13 1996-02-01 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Microbiological test method and reagents
WO1996022376A1 (en) 1995-01-20 1996-07-25 The Secretary Of State For Defence Mutant luciferases

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
A.R ARKIN ET AL., BIO-TECHNOLOGY, vol. 10, 1992, pages 297 - 300
BIOCHEM., vol. 38, 1999, pages 8271 - 8279
DEVEREUX ET AL., NUCLEIC ACID RESEARCH, vol. 12, 1984, pages 387 - 395
E. CONTI ET AL., STRUCTURE, vol. 4, 1996, pages 287 - 298
F. SANGER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 74, 1977, pages 5463 - 5467
L. YE ET AL., BIOCHIM. BIOPHYS ACTA, vol. 1339, 1997, pages 39 - 52
LIPMAN, D.J.; PEARSON, W.R.: "Rapid and Sensitive Protein Similarity Searches", SCIENCE, vol. 227, 1985, pages 1435 - 1441
M. FROMANT ET AL., ANAL. BIOCHEM., vol. 224, 1995, pages 347 - 353
S. CLIMIE ET AL., J. BIOL. CHEM., vol. 265, 1990, pages 18776 - 18779
SAMBROOK ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LABORATORY PRESS
W,. HUANG ET AL., ANAL. BIOCHEM., vol. 218, pages 454 - 457

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840730B2 (en) 2010-11-02 2017-12-12 Promega Corporation Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
US12215375B2 (en) 2010-11-02 2025-02-04 Promega Corporation Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
US8809529B2 (en) 2010-11-02 2014-08-19 Promega Corporation Imidazo[1,2-α]pyrazine derivatives
US9139836B2 (en) 2010-11-02 2015-09-22 Promega Corporation Imidazo[1,2-a]pyrazine derivatives
US9487520B2 (en) 2010-11-02 2016-11-08 Promega Corporation Coelenterazine derivatives and methods of using same
US12435354B2 (en) 2010-11-02 2025-10-07 Promega Corporation Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
US9938564B2 (en) 2010-11-02 2018-04-10 Promega Corporation Substituted imidazo[1,2-a]pyrazines for use in bioluminogenic methods
US11661623B2 (en) 2010-11-02 2023-05-30 Promega Corporation Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
US10774364B2 (en) 2010-11-02 2020-09-15 Promega Corporation Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
US9951373B2 (en) 2010-11-02 2018-04-24 Promega Corporation Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
CN102191213B (zh) * 2011-04-14 2012-10-03 中国科学院武汉病毒研究所 一种萤火虫荧光素酶的编码基因及制备方法和应用
CN102191213A (zh) * 2011-04-14 2011-09-21 中国科学院武汉病毒研究所 一种萤火虫荧光素酶的编码基因及制备方法和应用
US9927430B2 (en) 2014-01-29 2018-03-27 Promega Corporation Pro-substrates for live cell applications
US9790537B2 (en) 2014-01-29 2017-10-17 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements

Also Published As

Publication number Publication date
GB0016744D0 (en) 2000-08-30
GB9925161D0 (en) 1999-12-22
HK1055443A1 (zh) 2004-01-09
US20140186918A1 (en) 2014-07-03
JP2011083289A (ja) 2011-04-28
EP2284271A3 (de) 2012-03-07
EP2284271B1 (de) 2013-09-11
US8669087B1 (en) 2014-03-11
EP1935980B1 (de) 2013-07-17
EP1935980A1 (de) 2008-06-25
ZA200203170B (en) 2003-09-23

Similar Documents

Publication Publication Date Title
EP1224294B1 (de) Mutantenluciferase
US20140186918A1 (en) Luciferase mutant
White et al. Improved thermostability of the North American firefly luciferase: saturation mutagenesis at position 354
EP0751996B1 (de) Luziferasen
CA2283287C (en) Enzyme assays
KR20030051865A (ko) 단리된 루시퍼라제 및 그의 용도
Nazari et al. Step-wise addition of disulfide bridge in firefly luciferase controls color shift through a flexible loop: a thermodynamic perspective
JP2008289475A (ja) 最大発光波長がシフトした変異型ルシフェラーゼ
US10988741B2 (en) Mutated genes for the catalytic protein of Oplophorus luciferase and use thereof
EP1924702A2 (de) Ph-tolerante luciferase
US20150152395A1 (en) Chimeric luciferases
TWI239353B (en) Thermostable luciferase mutant enzymes, nucleic acids encoding them and the use thereof
HK1055443B (zh) 新型酶
Halliwell Protein engineering utilising single amino acid deletions within Photinus pyralis firefly luciferase
US10519428B2 (en) Mutated genes for the catalytic protein of oplophorus luciferase and use thereof
MXPA96004194A (en) Lucifera
Davis Improved Red-emitting Firefly Luciferase Mutant for Biotechnical Applications

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100923

AC Divisional application: reference to earlier application

Ref document number: 1935980

Country of ref document: EP

Kind code of ref document: P

Ref document number: 1224294

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/53 20060101AFI20120201BHEP

Ipc: C12N 9/02 20060101ALI20120201BHEP

Ipc: C12Q 1/66 20060101ALI20120201BHEP

17Q First examination report despatched

Effective date: 20120927

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20130408

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1935980

Country of ref document: EP

Kind code of ref document: P

Ref document number: 1224294

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 631657

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60048252

Country of ref document: DE

Effective date: 20131107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130918

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130911

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20130911

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 631657

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130911

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130911

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130911

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130911

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60048252

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140113

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130911

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131031

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131031

26N No opposition filed

Effective date: 20140612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130911

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60048252

Country of ref document: DE

Effective date: 20140612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131026

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131026

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20191029

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20191025

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20191028

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60048252

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20201025

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20201025